Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) - Zhou, C; Wu, Y L; Chen, G (Ann Oncol, 2015)
et al.